WORLD JOURNAL OF GASTROENTEROLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-06-07 145bda03m22暂无昵称

我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表::
一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表:
一审后director让Assigned to Editor for Revision是啥意思呢？

shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？

78 0

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-06-06 wanyu0330_14070335

如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊

79 0

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-06-06 wanyu0330_14070335

很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。

75 0

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-05-08 窝窝头1732

审稿速度:1.0 | 投稿命中率:50.0
经验分享：该杂志要求的材料比较多
只能有一个通讯作者
版面费极其贵
审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。

79 0

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-05-06 Hejoey

我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了

92 0

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-04-30 天下飘雪1212

这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意

77 0

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-04-15 天下飘雪1212

回顾性研究也需要知情同意吗

77 0

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-04-08 shunyi1058

一审后director让Assigned to Editor for Revision是啥意思呢？

103 0

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-03-14 ashleyjr

同问150****6990 2018-11-12 发表::
这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表:
这个杂志可以共一或者共同通讯吗？

150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？

267 0

[GetPortalCommentsPageByObjectIdResponse(id=571980, encodeId=96fb5e198018, content=我的也是，你现在有消息了吗？shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？shunyi1058 2019-04-08 00:00:00 发表: 一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=shunyi1058 2019-04-08 发表:: 一审后director让Assigned to Editor for Revision是啥意思呢？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/10/1b4eaa9a3c902dc1bb271e2257a06d89.jpg, createdBy=30395084506, createdName=145bda03m22暂无昵称, createdTime=Fri Jun 07 00:00:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571938, encodeId=8e795e19380b, content=如果是临床回顾性文章的话还要准备一堆材料，除了医学伦理证明，还有知情同意书、文章润色证明、统计学专家证明、各种作者签名和通讯作者签名什么的，最后还是被拒，坑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:41:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571937, encodeId=d3885e1937bf, content=很不好的投稿经历，还是约稿的，3天就有一个reviewer拒稿回复，拒稿的原因是说临床指标没有新颖，而且分析方法不对，但是编辑说一般要等1-3个reviewers结果才给最终答复，但是等了一个月，最后也只有刚开始的那个reviewer结果，也就是拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02449895, createdName=wanyu0330_14070335, createdTime=Thu Jun 06 10:38:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570610, encodeId=4aef5e0610a1, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：该杂志要求的材料比较多 只能有一个通讯作者 版面费极其贵 审稿意见相对专业，效率还可以，语言至少B吧，科学性也应该至少C。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59991700033, createdName=窝窝头1732, createdTime=Wed May 08 16:25:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570513, encodeId=23305e051351, content=我的文章里有meta分析，有基础，有临床…这属于什么文章啊，怎么准备材料…哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86262148316, createdName=Hejoey, createdTime=Mon May 06 00:00:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570248, encodeId=dce05e024826, content=这个期刊需要的材料特别多，前期投稿一定要做好充分的准备，不然还会打回来重新投稿，一定注意, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Tue Apr 30 00:00:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569559, encodeId=8d1256955940, content=回顾性研究也需要知情同意吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/504090121D232FF985B4F5BAC465785C/100, createdBy=f9142325582, createdName=天下飘雪1212, createdTime=Mon Apr 15 00:00:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569243, encodeId=7c39569243d9, content=一审后director让Assigned to Editor for Revision是啥意思呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab2452481, createdName=shunyi1058, createdTime=Mon Apr 08 00:00:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568095, encodeId=f79f56809572, content=同问150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？150****6990 2018-11-12 00:00:00 发表: 这个杂志可以共一或者共同通讯吗？, beContent=150****6990 2018-11-12 发表:: 这个杂志可以共一或者共同通讯吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568096, encodeId=ee7356809604, content=可以共同通讯么？ashleyjr 2019-03-14 发表:: 同问ashleyjr 2019-03-14 00:00:00 发表: 同问, beContent=ashleyjr 2019-03-14 发表:: 同问, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1e01696713, createdName=ashleyjr, createdTime=Thu Mar 14 00:00:00 CST 2019, time=2019-03-14, status=1, ipAttribution=)]

2019-03-14 ashleyjr

可以共同通讯么？ashleyjr 2019-03-14 发表::
同问ashleyjr 2019-03-14 00:00:00 发表:
同问

ashleyjr 2019-03-14 发表:: 同问

264 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务